share_log

Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $160

Benzinga ·  Dec 11, 2023 11:31

Truist Securities analyst Joon Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $220 to $160.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment